ArticleJournal of neuro-oncology2011
Which therapy works better in choroid plexus carcinomas?
Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Case Report:Frontiers in veterinary science · 2025Article
- Approaches to Minimise the Neurodevelopmental Impact of Choroid Plexus Carcinoma and Its Treatment.Life (Basel, Switzerland) · 2023Review
- Final results of the Choroid Plexus Tumor study CPT-SIOP-2000.Journal of neuro-oncology · 2022Article
- Choroid plexus carcinoma with leptomeningeal spread in an adult: a case report and review of the literature.Journal of medical case reports · 2021Review
- Choroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience.Journal of neuro-oncology · 2017Article
- Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma.Frontiers in pharmacology · 2017Article
- Response to combined radiotherapy and chemotherapy of a leptomeningeal spread from choroid plexus carcinoma: case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015Article
- Pediatric choroid plexus tumors: epidemiology, treatments, and outcome analysis on 202 children from the SEER database.Journal of neuro-oncology · 2015Article
- Current management of choroid plexus carcinomas.Neurosurgical review · 2014Review
- Clinical outcome of pediatric choroid plexus tumors: retrospective analysis from a single institute.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2014Article
- Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.Molecular diagnosis & therapy · 2013Review
- Loss of TP53 expression in immortalized choroid plexus epithelial cells results in increased resistance to anticancer agents.Journal of neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroid plexus carcinomas (CPCs) are rare tumors with dismal outcome. While it has been established that surgery, radiotherapy, and chemotherapy improve survival, the best chemotherapy drugs for treating this disease still need to be identified. Since CPC is too rare to permit a prospective clinical trial, we performed a meta-analysis to evaluate the effects of individual drugs in patients with CPCs. We expanded a pre-existing database and included all cases of choroid plexus tumors, identified in PubMed through the end of 2007, for a total of 906 patients. At first, we restricted the analysis to patients with histologically confirmed CPC (n = 361) and with residual tumor after surgery (n = 130/361 patients), and we compared response and survival between patients who received a particular drug and those who did not. Response to chemotherapy was documented in 43 patients. Of the drugs used in these patients, etoposide was associated with the highest response rate (17/36). Next survival was compared among all CPC. Kaplan-Meier curves and log-rank tests suggested a statistically significant treatment benefit for cyclophosphamide, etoposide, and carboplatin, while the effect of vincristine was found to be marginally significant (P = 0.07, log rank). Of these, only etoposide's effect could be confirmed in a limited Cox multiple regression analysis. In conclusion, etoposide should be included in future standard treatment protocols. However the survival rates are still unsatisfactory, and additional novel drugs should be studied in prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.